Adagene to Participate in Two Upcoming Investor Conferences

Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology firm focused on novel antibody-based cancer immunotherapies, will participate in two significant investor conferences in late February and early March 2026. Mickael Chane-Du, the Chief Strategy Officer, is set to engage in one-on-one meetings and a fireside chat during the Oppenheimer 36th Annual Healthcare Life Sciences Conference, scheduled for February 25, 2026, and the Leerink Global Healthcare Conference from March 8-11, 2026.

The Oppenheimer conference will feature Chane-Du on February 25 at 4:00 PM ET, while the Leerink Conference will host another session on March 9 at 4:20 PM ET. Both sessions will be available via webcasts, and interested parties can access them through Adagene's investor page. Additionally, the company recently showcased its innovative strategies at the Guggenheim Emerging Outlook: Biotech Summit in New York City.

Adagene's proprietary technology, including SAFEbody and Dynamic Precision Library (DPL), positions the firm at the forefront of therapeutic antibody development. Its SAFEbody platform addresses safety and tolerability issues of traditional antibody therapies by selectively targeting tumors while minimizing damage to healthy tissues. A pivotal asset in their pipeline is muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody currently undergoing clinical study for microsatellite stable metastatic colorectal cancer, and holding an FDA Fast Track designation.

Recognized for its collaboration with global partners, Adagene continues to explore how its advanced antibody technologies can meet pressing patient needs. For ongoing updates and more information, stakeholders can visit Adagene’s website and follow the firm on its social media platforms.

Adagene Inc. (Nasdaq: ADAG) is set to attract investor attention through its participation in two prominent healthcare investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Both events present pivotal opportunities for the company to showcase its innovative antibody platforms, particularly its SAFEbody technology, which aims to enhance the efficacy and safety of cancer immunotherapies.

Investors should view these conferences as critical touchpoints for gaining insights into Adagene’s strategic direction and clinical progress, especially regarding its lead program, muzastotug (ADG126), currently in advanced stages of clinical trials. The discussions led by Chief Strategy Officer Mickael Chane-Du will provide investors with updates on clinical milestones, partnership developments, and market positioning that could influence stock performance.

Given Adagene's cutting-edge technology aimed at addressing significant unmet needs in cancer treatment, its differentiation in the biotechnology space is noteworthy. The SAFEbody platform, with its ability to minimize off-target toxicity while maximizing therapeutic efficacy, positions Adagene as a potential leader in the immunotherapy landscape.

In preparation for the conferences, investors should closely monitor the company’s webcast presentations, which will likely clarify its operational strategies, pipeline advancements, and upcoming catalysts. Engaging with Adagene’s management during one-on-one meetings could yield additional valuable insights into the company’s trajectory and key performance indicators.

Furthermore, considering the volatility often associated with biotech stocks, a cautious approach is prudent. Investors might look for entry points during dips or after the conferences to capitalize on potential bullish trends following new data or partnership announcements. Overall, with its innovative approach and strategic focus, Adagene represents a promising investment opportunity in the dynamic biotech sector.